Advertisement

Picture EBD Group Asia Bio Partnering Forum 2024 Singapore 650x100px
Collaboration › Details

Prothena–JPMorgan Chase: investor conference, 201701 supply service Prothena presents at JP Morgan Healthcare Conference 2017

 

Period Period 2017-01-12
Region Region San Francisco, CA
  Country United States (USA)
Organisations Partner, 1st Prothena Corporation plc (Nasdaq: PRTA)
  Group Prothena (Group)
  Partner, 2nd J.P. Morgan Securities LLC
  Group JPMorgan Chase (Group)
Products Product J.P. Morgan 35th Annual Healthcare Conference 2017 San Francisco
  Product 2 therapeutic antibody
Persons Person Nguyen, Tran (Prothena 201701 CFO)
  Person 2 Rose, Ellen (Prothena 201701 Public Relations)
     

Prothena Corporation plc. (1/4/17). "Press Release: Prothena to Participate in the J.P. Morgan Healthcare Conference". Dublin.

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that members of its senior management team will present and participate in the 35th Annual J.P. Morgan Healthcare Conference on January 12th at 11:00 AM PT in San Francisco, CA.

A live webcast of the company presentation can be accessed through the investor relations section of the Company's website at www.prothena.com. Following the live presentation, a replay of the webcast will be available on the Company's website for at least 90 days following the presentation date.


About Prothena

Prothena Corporation plc is a global, late-stage clinical biotechnology company seeking to fundamentally change the course of progressive diseases with its clinical pipeline of novel therapeutic antibodies. Fueled by its deep scientific understanding built over decades of research in protein misfolding and cell adhesion — the root causes of many serious or currently untreatable amyloid and inflammatory diseases — Prothena is establishing a fully integrated research, development and commercial focus and has advanced several drug candidates into clinical studies while pursuing discovery of additional novel therapies. Our pipeline of antibody-based product candidates targets a number of potential indications including AL amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003), and ATTR amyloidosis (PRX004). For more information, please visit the company's website at www.prothena.com.


Contacts

Investors: Tran Nguyen, CFO
650-837-8535, IR@prothena.com

Media: Ellen Rose
650-922-2405, ellen.rose@prothena.com

   
Record changed: 2017-03-04

Advertisement

Picture EBD Group Bio-Europe Spring 2024 Barcelona 650x200px

More documents for Prothena (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture EBD Group Bio-Europe Spring 2024 Barcelona 650x300px




» top